dextroamphetamine has been researched along with Depressive Disorder, Major in 14 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
Excerpt | Relevance | Reference |
---|---|---|
"The use of traditional psychostimulants (methylphenidate and dexamphetamine) and stimulant-like drugs (modafinil and armodafinil) for the treatment of depression is a growing concern given the lack of research evidence supporting their effectiveness." | 4.93 | Stimulants for depression: On the up and up? ( Bassett, D; Boyce, P; Byrow, Y; Hopwood, M; Lyndon, W; Malhi, GS; Mulder, R; Murray, G; Porter, R; Singh, A, 2016) |
"Total sleep deprivation (TSD) results in an acute emotional perturbation, which yields a transient antidepressant effect." | 3.30 | Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder. ( Benes, H; Bhatacharya, A; Browning, M; Ceusters, M; de Boer, P; Drevets, WC; Jacobs, GE; Recourt, K; van der Ark, P; van Gerven, JMA; van Nueten, L, 2023) |
"This is the first report of the pharmacodynamic (PD) effects of the selective, potent and brain-penetrant P2X7 receptor (P2X7R) antagonist JNJ-54175446." | 2.94 | Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. ( de Boer, P; de Kam, M; Drevets, W; Jacobs, G; Kanhai, K; Ravenstijn, P; Recourt, K; Siebenga, P; Timmers, M; van der Aart, J; van Gerven, J; van Nueten, L; Zuiker, R, 2020) |
" By study phase, Eight of 27 (30%) patients remitted with initial dosing of tranylcypromine up to 60 mg/d, 6/18 (33%) remitted with above PDR dosing of tranylcypromine up to 120 mg/d, and 1/6 (17%) to adding dextroamphetamine." | 2.79 | How treatable is refractory depression? ( Deliyannides, DA; McGrath, PJ; Stewart, JW, 2014) |
"2% (53/88) receiving lisdexamfetamine dimesylate had ≥ 1 treatment-emergent adverse event, the most frequent with lisdexamfetamine dimesylate being dry mouth and headache (both 11." | 2.78 | A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. ( Cutler, AJ; Gao, J; Geibel, BB; Lasser, R; Patkar, AA; Richards, C; Sambunaris, A; Trivedi, MH, 2013) |
"Although there is no pharmacological treatment for autism spectrum disorder (ASD) itself, behavioral and pharmacological therapies have been used to address its symptoms and common comorbidities." | 1.62 | Medication Use in the Management of Comorbidities Among Individuals With Autism Spectrum Disorder From a Large Nationwide Insurance Database. ( Avillach, P; Feroe, AG; Greenspun, P; Gutiérrez-Sacristán, A; Kohane, IS; Mousavi, S; Surati, R; Uppal, N, 2021) |
"The pathophysiology of major depressive disorder (MDD) includes disturbances in several neuroanatomical substrates and neurotransmitter systems." | 1.33 | Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. ( Busto, UE; Graham, SJ; Herrmann, N; Hevenor, S; Mayberg, HS; Naranjo, CA; Tremblay, LK, 2005) |
"The authors attempted to treat Major Depressive Disorder (MDD) suboptimally responsive to one of the newer (second-generation) antidepressants by augmentation with a psychostimulant medication." | 1.30 | Psychostimulant augmentation of second generation antidepressants: a case series. ( Anand, VS; Masand, PS; Tanquary, JF, 1998) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (7.14) | 18.7374 |
1990's | 1 (7.14) | 18.2507 |
2000's | 3 (21.43) | 29.6817 |
2010's | 6 (42.86) | 24.3611 |
2020's | 3 (21.43) | 2.80 |
Authors | Studies |
---|---|
Recourt, K | 2 |
de Boer, P | 2 |
van der Ark, P | 1 |
Benes, H | 1 |
van Gerven, JMA | 1 |
Ceusters, M | 1 |
van Nueten, L | 2 |
Drevets, WC | 1 |
Bhatacharya, A | 1 |
Browning, M | 1 |
Jacobs, GE | 1 |
van der Aart, J | 1 |
Jacobs, G | 1 |
de Kam, M | 1 |
Drevets, W | 1 |
Kanhai, K | 1 |
Siebenga, P | 1 |
Zuiker, R | 1 |
Ravenstijn, P | 1 |
Timmers, M | 1 |
van Gerven, J | 1 |
Feroe, AG | 1 |
Uppal, N | 1 |
Gutiérrez-Sacristán, A | 1 |
Mousavi, S | 1 |
Greenspun, P | 1 |
Surati, R | 1 |
Kohane, IS | 1 |
Avillach, P | 1 |
McIntyre, RS | 1 |
Lee, Y | 1 |
Zhou, AJ | 1 |
Rosenblat, JD | 1 |
Peters, EM | 1 |
Lam, RW | 1 |
Kennedy, SH | 1 |
Rong, C | 1 |
Jerrell, JM | 1 |
Trivedi, MH | 2 |
Cutler, AJ | 1 |
Richards, C | 1 |
Lasser, R | 2 |
Geibel, BB | 1 |
Gao, J | 1 |
Sambunaris, A | 2 |
Patkar, AA | 1 |
Madhoo, M | 1 |
Keefe, RS | 1 |
Roth, RM | 1 |
Wu, J | 1 |
Anderson, CS | 1 |
Stewart, JW | 1 |
Deliyannides, DA | 1 |
McGrath, PJ | 1 |
Malhi, GS | 1 |
Byrow, Y | 1 |
Bassett, D | 1 |
Boyce, P | 1 |
Hopwood, M | 1 |
Lyndon, W | 1 |
Mulder, R | 1 |
Porter, R | 1 |
Singh, A | 1 |
Murray, G | 1 |
Ng, B | 1 |
Howland, RH | 1 |
Tremblay, LK | 1 |
Naranjo, CA | 1 |
Graham, SJ | 1 |
Herrmann, N | 1 |
Mayberg, HS | 1 |
Hevenor, S | 1 |
Busto, UE | 1 |
Pogarell, O | 1 |
Koch, W | 1 |
Pöpperl, G | 1 |
Tatsch, K | 1 |
Jakob, F | 1 |
Mulert, C | 1 |
Grossheinrich, N | 1 |
Rupprecht, R | 1 |
Möller, HJ | 1 |
Hegerl, U | 1 |
Padberg, F | 1 |
Ward, NG | 1 |
Lampe, TH | 1 |
Masand, PS | 1 |
Anand, VS | 1 |
Tanquary, JF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Exploratory Efficacy and Safety Study of SPD489 in Adults 18-55 Years With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant[NCT00905424] | Phase 2 | 246 participants (Actual) | Interventional | 2009-07-30 | Completed | ||
Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults With Clinically Significant, Persistent Executive Function Impairments (EFI) and Partial or Full Remission of [NCT00985725] | Phase 2 | 143 participants (Actual) | Interventional | 2009-10-29 | Completed | ||
A Pilot Study of Treatment for Refractory Depression With Sequential Trials of Tranylcypromine, Tranylcypromine Plus Dextroamphetamine, Tranylcypromine Plus Triiodothyronine.[NCT00296686] | Phase 4 | 31 participants (Actual) | Interventional | 2001-09-30 | Terminated (stopped due to Study is no longer funded.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. (NCT00905424)
Timeframe: Augmentation Baseline, 6 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Antidepressant + SPD489 (Non-remitters) | -7.1 |
Antidepressant + Placebo (Non-remitters) | -4.9 |
The HAM-D is a validated rating scale which consists of 17 items. Nine of the items are scored on a scale of 0-4 and 8 items are scored on a scale of 0-2 for a total scoring range of 0-52. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates increased severity of depression. In general, the lower the total score the less severe the depression. (NCT00905424)
Timeframe: Augmentation Baseline, 6 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Antidepressant + SPD489 (Non-remitters) | -4.9 |
Antidepressant + Placebo (Non-remitters) | -4.0 |
MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue. (NCT00905424)
Timeframe: Augmentation Baseline and 6 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Antidepressant + SPD489 (Non-remitters) | -5.3 |
Antidepressant + Placebo (Non-remitters) | -2.3 |
QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression. (NCT00905424)
Timeframe: Augmentation Baseline and 6 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Antidepressant + SPD489 (Non-remitters) | -2.4 |
Antidepressant + Placebo (Non-remitters) | -1.2 |
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment. (NCT00905424)
Timeframe: Augmentation Baseline, 6 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Antidepressant + SPD489 (Non-remitters) | -3.7 |
Antidepressant + Placebo (Non-remitters) | -1.7 |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. (NCT00905424)
Timeframe: Augmentation Baseline and 6 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Antidepressant + SPD489 (Remitters) | 0.1 |
Antidepressant + Placebo (Remitters) | -1.1 |
The HAM-D is a validated rating scale which consists of 17 items. Nine of the items are scored on a scale of 0-4 and 8 items are scored on a scale of 0-2 for a total scoring range of 0-52. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates increased severity of depression. In general, the lower the total score the less severe the depression. (NCT00905424)
Timeframe: Augmentation Baseline and 6 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Antidepressant + SPD489 (Remitters) | -0.8 |
Antidepressant + Placebo (Remitters) | -1.6 |
MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue. (NCT00905424)
Timeframe: Augmentation baseline and 6 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Antidepressant + SPD489 (Remitters) | -4.0 |
Antidepressant + Placebo (Remitters) | -0.2 |
QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression. (NCT00905424)
Timeframe: Augmentation baseline and 6 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Antidepressant + SPD489 (Remitters) | -1.9 |
Antidepressant + Placebo (Remitters) | -0.4 |
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment. (NCT00905424)
Timeframe: Augmentation Baseline and 6 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Antidepressant + SPD489 (Remitters) | -1.6 |
Antidepressant + Placebo (Remitters) | -0.6 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00905424)
Timeframe: 6 weeks
Intervention | Percent of Participants (Number) |
---|---|
Antidepressant + SPD489 (Non-remitters) | 60.0 |
Antidepressant + Placebo (Non-remitters) | 45.3 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00905424)
Timeframe: 6 weeks
Intervention | Percent of participants (Number) |
---|---|
Antidepressant + SPD489 (Remitters) | 65.2 |
Antidepressant + Placebo (Remitters) | 52.4 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00905424)
Timeframe: Augmentation baseline
Intervention | Percent of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Normal, not at all ill | Borderline mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
Antidepressant + Placebo (Non-remitters) | 1.6 | 12.5 | 34.4 | 48.4 | 3.1 | 0 | 0 |
Antidepressant + SPD489 (Non-remitters) | 1.5 | 20.0 | 40.0 | 32.3 | 6.2 | 0 | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00905424)
Timeframe: 6 weeks
Intervention | Percent of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Normal, not at all ill | Borderline mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
Antidepressant + Placebo (Non-remitters) | 14.5 | 24.2 | 22.6 | 29.0 | 9.7 | 0 | 0 |
Antidepressant + SPD489 (Non-remitters) | 27.0 | 31.7 | 30.2 | 9.5 | 1.6 | 0 | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00905424)
Timeframe: Augmentation Baseline
Intervention | Percent of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Normal, not at all ill | Borderline mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
Antidepressant + Placebo (Remitters) | 23.8 | 71.4 | 4.8 | 0 | 0 | 0 | 0 |
Antidepressant + SPD489 (Remitters) | 26.1 | 47.8 | 21.7 | 4.3 | 0 | 0 | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00905424)
Timeframe: 6 weeks
Intervention | Percent of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Normal, not at all ill | Borderline mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
Antidepressant + Placebo (Remitters) | 61.9 | 23.8 | 9.5 | 4.8 | 0 | 0 | 0 |
Antidepressant + SPD489 (Remitters) | 50.0 | 36.4 | 13.6 | 0 | 0 | 0 | 0 |
BRIEF-A is a validated 75-item questionnaire composed of three scales (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to develop interpretive reports. Lower scores reflect better functioning. (NCT00905424)
Timeframe: Augmentation Baseline and 6 weeks
Intervention | Units on a scale (Least Squares Mean) | ||
---|---|---|---|
Global Executive Composite | Behavioral Regulation Index | Metacognition Index | |
Antidepressant + Placebo (Non-remitters) | -1.7 | -1.7 | -1.5 |
Antidepressant + SPD489 (Non-remitters) | -4.7 | -3.7 | -4.8 |
BRIEF-A is a validated 86-item questionnaire composed of three scales (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Lower scores reflect better functioning. (NCT00905424)
Timeframe: Augmentation baseline and 6 weeks
Intervention | Units on a scale (Least Squares Mean) | ||
---|---|---|---|
Global Executive Composite | Behavioral Regulation Index | Metacognition Index | |
Antidepressant + Placebo (Remitters) | -2.7 | -1.5 | -3.4 |
Antidepressant + SPD489 (Remitters) | -0.9 | -0.4 | -1.1 |
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity. (NCT00985725)
Timeframe: Baseline and week 11
Intervention | Scores on a scale (Mean) |
---|---|
Lisdexamfetamine Dimesylate (LDX) | -9.4 |
Placebo | -5.9 |
BRIEF-A Global Executive Composite assesses behavioral aspects of executive function. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment. (NCT00985725)
Timeframe: Baseline and week 9
Intervention | T-scores (Least Squares Mean) |
---|---|
Lisdexamfetamine Dimesylate (LDX) | -21.2 |
Placebo | -13.2 |
This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning. (NCT00985725)
Timeframe: Baseline and week 9
Intervention | Scores on a scale (Mean) |
---|---|
Lisdexamfetamine Dimesylate (LDX) | 2.5 |
Placebo | 2.4 |
This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning. (NCT00985725)
Timeframe: Baseline and week 9
Intervention | Scores on a scale (Mean) |
---|---|
Lisdexamfetamine Dimesylate (LDX) | 2.7 |
Placebo | 1.6 |
The EWPS quantifies work performance, productivity attitudes and behaviors assessing 25 items on a scale ranging from 0 (high performance) to 4 (lowest performance). Scores range from 0 to 100 with 100 representing lowest productivity. (NCT00985725)
Timeframe: Baseline and up to 9 weeks/Endpoint
Intervention | Scores on a scale (Least Squares Mean) |
---|---|
Lisdexamfetamine Dimesylate (LDX) | -20.4 |
Placebo | -15.9 |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. (NCT00985725)
Timeframe: Baseline and week 9
Intervention | Scores on a scale (Least Squares Mean) |
---|---|
Lisdexamfetamine Dimesylate (LDX) | -5.0 |
Placebo | -3.1 |
The STS is an 8-question clinician-rated assessment of suicidal ideation, suicidal behavior, and accidents. The items are scored on a 5-point Likert scale from 0 (not at all) to 4 (extremely) and summed to produce a total score ranging from 0 to 32. Lower scores indicate reduced suicidal tendencies. (NCT00985725)
Timeframe: Baseline and week 9
Intervention | Scores on a scale (Mean) |
---|---|
Lisdexamfetamine Dimesylate (LDX) | -0.1 |
Placebo | 0.0 |
The GAD-7 is a 7-item self-report questionnaire for assessing anxiety severity. Each item is scored using a scale that ranges from 0 (not at all) to 3 (nearly every day) with total scores ranging from 0 to 21. Lower scores indicate a reduction in anxiety. (NCT00985725)
Timeframe: Baseline and week 9
Intervention | Scores on a scale (Mean) |
---|---|
Lisdexamfetamine Dimesylate (LDX) | -4.4 |
Placebo | -3.8 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00985725)
Timeframe: Week 9
Intervention | percentage of participants (Number) |
---|---|
Lisdexamfetamine Dimesylate (LDX) | 60.6 |
Placebo | 38.9 |
BRIEF-A is a validated 75-item questionnaire. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment. (NCT00985725)
Timeframe: Baseline and week 9
Intervention | T-scores (Least Squares Mean) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Behavioral recognition index | Inhibit subscale | Shift subscale | Emotional control subscale | Self-monitor subscale | Metacognition index | Initiate subscale | Working memory subscale | Plan/Organize subscale | Task monitor subscale | Organization of materials subscale | |
Lisdexamfetamine Dimesylate (LDX) | -17.4 | -13.5 | -16.2 | -13.8 | -13.8 | -21.1 | -19.4 | -20.1 | -18.7 | -16.8 | -15.2 |
Placebo | -12.3 | -9.3 | -10.6 | -10.1 | -10.7 | -12.2 | -10.8 | -11.0 | -11.3 | -11.9 | -8.2 |
This measures the speed and accuracy of basic mental functions. Scores are normalized from raw scores and present an age matched score relative to other people in a normative sample. Scores are normalized with a mean of 100 and standard deviation of 15. Scores < 70 indicate likely deficit and impairment, and scores > 110 indicate high function and capacity. Higher scores are better. (NCT00985725)
Timeframe: Baseline and up to 9 weeks/Endpoint
Intervention | Response scores (Mean) | ||
---|---|---|---|
Complex information speed processing index | Executive function index | Neurocognitive index | |
Lisdexamfetamine Dimesylate (LDX) | 8.7 | 11.0 | 11.5 |
Placebo | 3.7 | 6.0 | 2.5 |
The Q-LES-Q is a 93-item self-report questionnaire on quality of life and health. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good) with a total score ranging from 93 to 465. Higher scores indicate greater satisfaction. (NCT00985725)
Timeframe: Baseline and up to 9 weeks/Endpoint
Intervention | Scores on a scale (Mean) | |
---|---|---|
Physical health activities | Overall life satisfaction | |
Lisdexamfetamine Dimesylate (LDX) | 17.9 | 12.1 |
Placebo | 8.2 | 9.1 |
The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. Each of the 12 items is scored using various scales with a total score ranging from 0 (lowest level of health) to 100 (highest level of health). (NCT00985725)
Timeframe: Baseline and week 9
Intervention | Scores on a scale (Mean) | |
---|---|---|
Aggregate physical | Aggregate mental | |
Lisdexamfetamine Dimesylate (LDX) | -0.10 | 0.69 |
Placebo | -0.23 | 0.63 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00985725)
Timeframe: Up to 9 weeks/Endpoint
Intervention | percentage of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Normal, not at all ill | Borderline mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
Lisdexamfetamine Dimesylate (LDX) | 21.7 | 40.6 | 20.3 | 14.5 | 2.9 | 0.0 | 0.0 |
Placebo | 15.9 | 23.2 | 24.6 | 34.8 | 1.4 | 0.0 | 0.0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00985725)
Timeframe: Baseline
Intervention | percentage of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Normal, not at all ill | Borderline mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
Lisdexamfetamine Dimesylate (LDX) | 0.0 | 7.0 | 42.3 | 45.1 | 4.2 | 1.4 | 0.0 |
Placebo | 2.8 | 8.3 | 36.1 | 48.6 | 4.2 | 0.0 | 0.0 |
2 reviews available for dextroamphetamine and Depressive Disorder, Major
Article | Year |
---|---|
The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Dextroamphetami | 2017 |
Stimulants for depression: On the up and up?
Topics: Amphetamine; Antidepressive Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System S | 2016 |
5 trials available for dextroamphetamine and Depressive Disorder, Major
Article | Year |
---|---|
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.
Topics: Central Nervous System; Depressive Disorder, Major; Dextroamphetamine; Humans; Purinergic P2X Recept | 2023 |
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
Topics: Adolescent; Adult; Central Nervous System Stimulants; Depressive Disorder, Major; Dextroamphetamine; | 2020 |
A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Central Nervous System Stimulants; Cita | 2013 |
Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.
Topics: Adult; Antidepressive Agents; Cognition Disorders; Depressive Disorder, Major; Dextroamphetamine; Do | 2014 |
How treatable is refractory depression?
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Depressive Disorder, Major; Depress | 2014 |
7 other studies available for dextroamphetamine and Depressive Disorder, Major
Article | Year |
---|---|
Medication Use in the Management of Comorbidities Among Individuals With Autism Spectrum Disorder From a Large Nationwide Insurance Database.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; | 2021 |
Is there a role for psychostimulants in old age depression and apathy?
Topics: Aged; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Dis | 2009 |
The use of dopaminergic and stimulant drugs for the treatment of depression.
Topics: Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2012 |
Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe.
Topics: Adult; Affective Symptoms; Brain; Corpus Striatum; Depressive Disorder, Major; Dextroamphetamine; Di | 2005 |
Acute prefrontal rTMS increases striatal dopamine to a similar degree as D-amphetamine.
Topics: Benzamides; Central Nervous System Stimulants; Corpus Striatum; Depressive Disorder, Major; Dextroam | 2007 |
A trial of dextroamphetamine in patients with involutional agitated depression.
Topics: Aged; Depressive Disorder, Major; Desipramine; Dextroamphetamine; Female; Humans; Middle Aged; Psych | 1982 |
Psychostimulant augmentation of second generation antidepressants: a case series.
Topics: Adult; Antidepressive Agents, Second-Generation; Central Nervous System Stimulants; Depressive Disor | 1998 |